Last $11.15 USD
Change Today 0.00 / 0.00%
Volume 0.0
BMICY On Other Exchanges
Symbol
Exchange
OTC US
OTC US
Frankfurt
As of 4:30 PM 09/4/14 All times are local (Market data is delayed by at least 15 minutes).

bionomics limited-adr (BMICY) Snapshot

Open
--
Previous Close
$11.15
Day High
--
Day Low
--
52 Week High
03/12/14 - $13.23
52 Week Low
06/23/14 - $8.40
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
20.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIONOMICS LIMITED-ADR (BMICY)

Related News

No related news articles were found.

bionomics limited-adr (BMICY) Related Businessweek News

No Related Businessweek News Found

bionomics limited-adr (BMICY) Details

Bionomics Limited discovers and develops biopharmaceuticals for the treatment of cancer and disorders of the central nervous system in Australia, France, and the United States. The company develops small molecule and antibody therapeutics in the areas of cancer, anxiety, depression, and Alzheimer's disease. Its oncology approach includes cancer stem cell therapeutics, as well as vascular disruption in solid tumors. The company’s product pipeline includes BNC105, a novel compound in Phase II clinical trials to disrupt the blood vessels that nourish tumours in cancer treatment; and BNC101, a monoclonal antibody that targets cancer stem cells. It is also developing BNC210/IW-2143 for the treatment of anxiety disorders; BNC375, a small molecule therapeutic for the treatment of cognitive impairment in Alzheimers's disease; and Kv1.3 inhibitors for the treatment of inflammatory disorders. In addition, the company, through its subsidiary, Neurofit SAS, offers contract research services. It has collaboration, research, and licensing agreements with Ironwood Pharmaceuticals, Inc.; Merck & Co.; Cancer Therapeutics Cooperative Research Center; Genmab A/S; Laboratory Corporation of America; Athena Diagnostics, Inc.; and Genetic Technologies Limited. The company was founded in 1998 and is based in Thebarton, Australia.

Founded in 1998

bionomics limited-adr (BMICY) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$407.6K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$160.8K
Chief Medical Officer
Total Annual Compensation: A$378.9K
Head of Neurofit Research
Total Annual Compensation: A$188.7K
Vice President of Research & Development
Total Annual Compensation: A$208.3K
Compensation as of Fiscal Year 2014.

bionomics limited-adr (BMICY) Key Developments

Bionomics to Progress BNC210 in Clinical Trials

Bionomics Limited announced that it will accelerate and progress BNC210 into further human clinical trials expected to commence before the end of the year 2014. In January 2012 Bionomics entered into a collaboration, research & licensing agreement with Ironwood Pharmaceuticals, Inc, for the worldwide development and commercialization of BNC210. Bionomics and Ironwood have now mutually agreed to terminate this arrangement. Ironwood will retain a royalty interest in BNC210 whilst Bionomics has re-acquired exclusive worldwide rights to develop, commercialize and partner BNC210. Bionomics intends to progress the clinical development of BNC210 to significantly enhance its value prior to further partnering, building on the substantial progress already made through the Ironwood collaboration. Bionomics has received approval to commence a phase Ib clinical trial in France to be conducted by Biotrial International Limited. The trial will examine target engagement by BNC210, based on its mechanism of action. Details of the trial are provided in the clinical appendix following this announcement. It is anticipated that this trial will allow further refinement of BNC210 dose levels to be evaluated in Phase II. In addition Bionomics will shortly make a submission to commence a phase II trial in patients with anxiety. Pending approval, this trial is anticipated to commence in first quarter of 2015. Clinical Trial Appendix: Bionomics is conducting a single-centre Phase Ib multiple ascending dose clinical trial (BNC210.005) with BNC210 to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy male volunteers. Primary Endpoint: Safety and tolerability of multiple ascending oral doses of BNC210 in healthy adult male subjects. Secondary Endpoints: Preliminary pharmacokinetic profile of multiple ascending doses of BNC210. Pharmacodynamic profile of multiple ascending oral doses of BNC210 on cognitive functions. Pharmacodynamic profile of multiple administrations of the higher dose on nicotine shift. Four groups of subjects will be enrolled to receive one of each of four doses of BNC210 or placebo, twice a day for eight days. All subjects on the study will undergo a standard battery of pharmacodynamic assessments measuring cognitive parameters: Choice Reaction Time, Digit Vigilance, Rapid Visual Information Processing, Learning Memory Test, Numeric Working Memory test and Spatial Working Memory test, or subjective feelings produced by the drug: Bond and Lader Visual Analogue Scale, and Addiction Research Centre Inventory (ARCI) 49.

Bionomics Ltd., Annual General Meeting, Nov 12, 2014

Bionomics Ltd., Annual General Meeting, Nov 12, 2014., at 10:00 AUS Eastern Standard Time. Location: Wheat and Wool Room at the Intenational Melbourne The Rialto. Agenda: To receive and consider the company's financial report for the financial year ended June 30, 2014 and the accompanying Director’s report and auditor's report.; to consider adoption of remuneration report; to consider re-election of Non-Executive Director - Mr. Trevor Tappenden; to consider approval of proposed issue of share options to Dr. Deborah Rathjen; to consider approval of Bionomics Limited Employee Share Plan; and to consider approval of Bionomics Limited Employee Share Option Plan.

Bionomics Presents BNC105 Phase II Renal Cancer Trial Biomarker Data

Bionomics Limited presented new important data from the DisrupTOR-1 trial of BNC105 in patients with metastatic renal cancer at the European Society for Medical Oncology congress in Madrid, Spain. The data emphasizes the plasma biomarker profile associated with favourable outcomes for patients treated with BNC105. Throughout the clinical trials of BNC105 Bionomics has analyzed a panel of blood biomarkers. This was done to detect changes resulting from the administration of BNC105 and to determine whether such changes can indicate BNC105 clinical benefit. A most exciting aspect of this biomarker analysis has emerged from the randomised Phase II DisrupTOR-1 trial. As reported in March, 136 patients were enrolled and segregated in two treatment arms (69 in the BNC105 + Afinitor arm and 67 in the Afinitor-only arm). The primary endpoint of the study was to improve Progression Free Survival (PFS) from 36% at six months in the Afinitor-only arm to 60% PFS in the BNC105 + Afinitor arm. The initial data indicated that, in an unselected population, the proportion of PFS patients were similar between the two arms. However, blood samples were obtained from 44 patients before and after treatment with BNC105 in the BNC105 + Afinitor arm. This large sample size enabled statistical correlation of blood biomarker changes with disease status at six months of treatment. This correlation analysis revealed four biomarkers can be used to significantly enrich treatment success for this patient group treated with BNC105 plus Afinitor. 57% of patients were positive for the 4 biomarker signature, with 60% of these being disease free at six months. In contrast, only 5% of the patients that were negative for the 4 biomarker signature were disease free at six months. It is noteworthy that for this sizeable patient group the 60% six month PFS primary endpoint target was achieved.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMICY:US $11.15 USD 0.00

BMICY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BMICY.
View Industry Companies
 

Industry Analysis

BMICY

Industry Average

Valuation BMICY Industry Range
Price/Earnings 55.2x
Price/Sales 7.0x
Price/Book 3.9x
Price/Cash Flow 54.9x
TEV/Sales 6.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIONOMICS LIMITED-ADR, please visit www.bionomics.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.